Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: a systematic review
Background Since their first introduction in clinical practice, immune checkpoint inhibitors
showed limited benefit in patients with NSCLC harboring EGFR mutations. With the rationale …
showed limited benefit in patients with NSCLC harboring EGFR mutations. With the rationale …
Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
D Yan - Biomedicines, 2023 - mdpi.com
EGFR tyrosine kinase inhibitors (TKIs) are the preferred initial treatment for non-small cell
lung cancer (NSCLC) patients harboring sensitive EGFR mutations. Sadly, remission is …
lung cancer (NSCLC) patients harboring sensitive EGFR mutations. Sadly, remission is …
[HTML][HTML] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects
H Dickerson, A Diab, O Al Musaimi - International Journal of Molecular …, 2024 - mdpi.com
Tyrosine kinase inhibitors (TKIs) have emerged as a leading targeted cancer therapy,
reducing the side effects often seen with non-targeted treatments, especially the damage to …
reducing the side effects often seen with non-targeted treatments, especially the damage to …
It is too Early to Say NO IMMUNOTHERAPY for EGFR‐Mutant NSCLC Patients
DAN YAN - 2023 - preprints.org
EGFR tyrosine kinase inhibitors (TKIs) are the preferred initial treatment for non-small cell
lung cancer (NSCLC) patients harboring EGFR mutations. However, remission is transient …
lung cancer (NSCLC) patients harboring EGFR mutations. However, remission is transient …